Intellia's in-body CRISPR therapy achieves first Phase 3 success

Intellia announced that its experimental in vivo CRISPR gene‑editing therapy has completed a Phase 3 trial with positive results.

This is the first instance of a CRISPR‑based treatment delivered directly inside the body reaching this milestone, showing the technology can work in a large clinical study.

The favorable readout moves the candidate closer to a potential FDA filing, although formal regulatory review and approval are still required.

The achievement is seen as a significant step for gene‑editing therapeutics and could accelerate development of similar approaches across the industry.